SCHEMBL5499264

SCHEMBL5499264

CN1CCN(Cc2ccc(C(=O)Nc3ccc(Nc4ncc(-c5ccsc5)cn4)cc3)cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 8/20 0.52
BCR P11274 5/20 0.52
PDGFRA P16234 4/20 0.52
PDGFRB P09619 3/20 0.52
SRC P12931 3/20 0.52
SYK P43405 2/20 0.52
MAPK14 Q16539 3/20 0.51
KIT P10721 9/20 0.51
FLT3 P36888 2/20 0.51
LCK P06239 4/20 0.51
CSF1R P07333 4/20 0.51
ABL2 P42684 4/20 0.51
EGFR P00533 3/20 0.51
DDR2 Q16832 3/20 0.51
ERBB2 P04626 2/20 0.51
FYN P06241 2/20 0.51
LYN P07948 2/20 0.51
FGR P09769 2/20 0.51
BRAF P15056 2/20 0.51
NQO2 P16083 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5500661 0.91 ABL1 (0.64) ABL1BCRPDGFRAPDGFRBSRC
SCHEMBL5495979 0.89 ABL1 (0.58) ABL1BCRPDGFRAPDGFRBSRC
SCHEMBL5496170 0.82 MGLL (0.48) PDGFRBKITKDRLMNAHDAC6
SCHEMBL5495338 0.79 KDM4E (0.47) ABL1BCRPDGFRAPDGFRBMAPK14
SCHEMBL5499926 0.79 POLB (0.51) ABL1PDGFRBKDRCA12CA1
SCHEMBL4901725 0.77 ABL1 (0.72) ABL1BCRPDGFRAPDGFRBSRC
SCHEMBL29836713 0.77 SRC (0.57) ABL1BCRPDGFRAPDGFRBSRC
SCHEMBL4902292 0.76 ABL1 (0.86) ABL1BCRPDGFRAPDGFRBSRC
SCHEMBL24024030 0.75 RAB9A (0.73) BTKHDAC6
SCHEMBL14845834 0.75 BTK (0.67) MAPK14LMNABTKHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US claimed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP claimed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO claimed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP disclosed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293484-A1 Thiophene Heteroaryl Amines TTK, CHEK2, ABL1 ABL1 3/4885BCR 1003/4885PDGFRA 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.